Metachronous occurrence of main-duct intraductal papillary mucinous neoplasm (IPMN) and adenocarcinoma in a chronic pancreatitis patient: A case report.

RATIONALE: Chronic pancreatitis (CP) is a risk factor for developing pancreatic ductal adenocarcinoma (PDAC). In addition, a patient with partial pancreatectomy for intraductal papillary mucinous neoplasm (IPMN) can also lead to PDAC. In contrast, IPMN is a distinct disease entity, independent of CP, and there have been few reports that CP is the cause of IPMN. To the best of our knowledge, this is the first clinical case report of the metachronous occurrence of main-duct IPMN and PDAC with a 9 and half-year interval in a patient with chronic alcoholic pancreatitis. PATIENT CONCERNS: A 50-year-old man with a long medical history of recurrent alcoholic pancreatitis and hepatitis over a decade was diagnosed with another episode of acute pancreatitis based on laboratory findings and clinical symptoms. The patient underwent pylorus-preserving pancreaticoduodenectomy (PPPD) for a small nodular lesion in the main duct of the pancreatic head and was diagnosed with main-duct IPMN low-grade dysplasia and associated fibrosing CP. Nine and a half years later, a 59-year-old man lost 7 kg over 3 months and was diagnosed with new-onset diabetes mellitus. DIAGNOSIS: The patient was diagnosed with metachronous, well-differentiated PDAC with concomitant CP. INTERVENTIONS: The patient underwent radical antegrade modular pancreatosplenectomy (RAMPS) for a small nodular mass in the remnant pancreas. OUTCOMES: The patient was healthy for 44 months without evidence of tumor recurrence during clinical follow-up examinations including laboratory findings, tumor marker, and imaging studies. LESSONS: Early diagnosis of metachronous pancreatic neoplasia in a patient with chronic pancreatitis could be made by correlating newly developed clinical symptoms and signs with careful radiological examinations.

Erratum: Author's research-fund support notation correction. Mass forming chronic pancreatitis mimicking pancreatic cystic neoplasm: A case report World J Gastroenterology 2018; Jan 14; 24 (2): (297-302).

[This corrects the article on p. 297 in vol. 24, PMID: 29375215.].

Mass forming chronic pancreatitis mimicking pancreatic cystic neoplasm: A case report.

Mass forming chronic pancreatitis is very rare. Diagnosis could be done by the pathologic findings of focal inflammatory fibrosis without evidence of tumor in pancreas. A 34-year-old man presented with right upper abdominal pain for a few weeks and slightly elevated bilirubin level on clinical findings. Radiological findings of multidetector-row computed tomography, magnetic resonance (MR) imaging with MR cholangiopancreatography and endoscopic ultrasonography revealed focal branch pancreatic duct dilatation with surrounding delayed enhancing solid component at uncinate process and head of pancreas, suggesting branch duct type intraductal papillary mucinous neoplasm. Surgery was done and pathology revealed the focal chronic inflammation, fibrosis, and branch duct dilatation. Herein, I would like to report the first case report of mass forming chronic pancreatitis mimicking pancreatic cystic neoplasm.

A clinical study of cutaneous adverse reactions to nonionic contrast media in Korea.

BACKGROUND: The use of intravenous contrast media (CM) has increased for the diagnosis of several diseases. The newly developed low osmolar nonionic contrast agents cause significantly decreased adverse reactions than the higher osmolar ones. However, adverse reactions may still occur, ranging in severity from minor side effects to severe complications. However, there have been few reports about cutaneous adverse reactions (CARs) to nonionic monomer CM. OBJECTIVE: The purpose of this study was to evaluate clinical features of CAR to intravenous nonionic monomer CM. METHODS: A total 47,338 examinees underwent intravenous iodinated contrast-enhanced computed tomography scan using nonionic monomer CM. Among the adverse reactions to the CM, we divided them into cutaneous or noncutaneous and immediate (<1 hr) or late (≥1 hr) adverse reactions. RESULTS: Adverse reactions were noted in 62 cases out of the total 47,338 cases; 50 cases (80.7%) were categorized CARs. Among them, there were 24 male and 26 female patients. There was no significant difference between the sexes, and CARs occurred in all age groups. The highest occurrence was in the age range of 50~59 years. CARs included urticaria (78%), angioedema (10%), maculopapular rash (8%), erythema (2%), and pruritus without rash (2%). Immediate reactions were 92% (46 cases), while late reactions were 8% (4 cases). CONCLUSION: CARs to nonionic monomer CM accounted for most of the adverse reactions (80.7%) and urticaria was the most common.

Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.

PURPOSE: The performance of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT) has been not established for the evaluation of recurrent colorectal cancer. The aim of this study was to evaluate the diagnostic value of FDG PET/CT in postoperative colorectal cancer patients with normal carcinoembryonic antigen (CEA) levels. METHODS: This retrospective study was conducted on 63 FDG PET/CT cases, involving postoperative colorectal cancer patients suspected of having recurrent or metastatic lesions with normal CEA levels. The diagnostic performance of FDG PET/CT was evaluated based on diverse suspected conditions, using physical examination, a conventional imaging work-up, and endoscopy. Histopathology, a clinical imaging work-up (including an FDG PET/CT examination), and determination of tumor marker levels during the follow-up served as the reference standard. RESULTS: The sensitivity, specificity, and accuracy for FDG PET/CT were 95, 76.6, and 88.8% for a lesion-by-lesion analysis, and 96.3, 86.1, and 90.5% for a case-by-case analysis, respectively. Three false-negative lesions among 107 suspected recurrent findings were identified as compared with nine false-positive lesions. For radiologically suspected recurrent or metastatic conditions, FDG PET/CT diagnostic performance was superior to radiological image modalities, for both lesion-by-lesion and case-by-case analyses. On follow-up of patients with normal CEA levels, but high CA19-9 levels, the use of FDG PET/CT detected true-positive findings in 63.3% of cases. CONCLUSION: FDG PET/CT is a valuable tool to distinguish recurrence or metachronous tumor from postoperative changes or other benign lesions in postoperative colorectal cancer patients with normal CEA levels and radiologically or clinically suspicious lesions.